Public Employees Retirement System of Ohio Has $9.78 Million Position in DexCom, Inc. (NASDAQ:DXCM)

Public Employees Retirement System of Ohio decreased its position in DexCom, Inc. (NASDAQ:DXCM - Free Report) by 15.8% in the 3rd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 145,923 shares of the medical device company's stock after selling 27,286 shares during the period. Public Employees Retirement System of Ohio's holdings in DexCom were worth $9,783,000 as of its most recent SEC filing.

Other hedge funds also recently modified their holdings of the company. Migdal Insurance & Financial Holdings Ltd. bought a new position in shares of DexCom in the second quarter valued at approximately $25,000. Sachetta LLC increased its holdings in DexCom by 255.2% during the 2nd quarter. Sachetta LLC now owns 238 shares of the medical device company's stock valued at $27,000 after purchasing an additional 171 shares in the last quarter. Riverview Trust Co raised its position in DexCom by 100.4% in the 3rd quarter. Riverview Trust Co now owns 463 shares of the medical device company's stock valued at $31,000 after purchasing an additional 232 shares during the last quarter. DT Investment Partners LLC boosted its stake in DexCom by 492.2% in the second quarter. DT Investment Partners LLC now owns 379 shares of the medical device company's stock worth $43,000 after purchasing an additional 315 shares in the last quarter. Finally, RPg Family Wealth Advisory LLC bought a new stake in shares of DexCom during the third quarter worth $57,000. Institutional investors own 97.75% of the company's stock.

Insider Buying and Selling

In related news, EVP Sadie Stern sold 4,259 shares of the stock in a transaction that occurred on Wednesday, November 20th. The stock was sold at an average price of $74.73, for a total transaction of $318,275.07. Following the completion of the sale, the executive vice president now directly owns 71,192 shares of the company's stock, valued at approximately $5,320,178.16. This represents a 5.64 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. 0.30% of the stock is currently owned by company insiders.

DexCom Trading Down 1.9 %

Shares of NASDAQ:DXCM traded down $1.54 during mid-day trading on Thursday, reaching $78.93. The stock had a trading volume of 3,209,214 shares, compared to its average volume of 3,888,470. The firm has a market cap of $30.83 billion, a PE ratio of 47.26, a price-to-earnings-growth ratio of 2.38 and a beta of 1.12. The firm has a 50 day simple moving average of $73.58 and a two-hundred day simple moving average of $84.99. The company has a current ratio of 2.46, a quick ratio of 2.12 and a debt-to-equity ratio of 1.23. DexCom, Inc. has a twelve month low of $62.34 and a twelve month high of $142.00.

Analyst Ratings Changes

A number of research firms recently issued reports on DXCM. Citigroup lifted their price target on DexCom from $85.00 to $91.00 and gave the company a "buy" rating in a report on Wednesday. Piper Sandler reiterated an "overweight" rating and set a $90.00 target price on shares of DexCom in a research report on Monday, August 26th. Royal Bank of Canada decreased their price target on shares of DexCom from $120.00 to $115.00 and set an "outperform" rating on the stock in a research note on Friday, October 25th. Leerink Partners reduced their price objective on DexCom from $90.00 to $87.00 and set an "outperform" rating on the stock in a report on Friday, October 25th. Finally, JPMorgan Chase & Co. increased their price objective on DexCom from $75.00 to $85.00 and gave the company a "neutral" rating in a research report on Friday, October 25th. Seven investment analysts have rated the stock with a hold rating, eleven have issued a buy rating and one has assigned a strong buy rating to the company's stock. Based on data from MarketBeat.com, DexCom currently has an average rating of "Moderate Buy" and a consensus price target of $98.00.

About DexCom

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.